Congratulations to Agios Pharmaceuticals for receiving FDA approval of IDHIFA for the treatment of acute myeloid leukemia
Read More
Third Rock launches Tango Therapeutics with $55M Series A to develop novel medicines designed to target cancer vulnerabilities
Read More
Third Rock Launches Goldfinch Bio with $55M Series A to Develop Precision Therapies for Kidney Disease
Read More
Third Rock launches Magenta Therapeutics with $48.5M to Apply New Stem Cell Science to Reboot the Immune System
Read More
Andrew Stricos, who has Huntington’s disease, and his wife tell their story at a luncheon hosted by Third Rock
Watch the Video
Transforming Healthcare
44
Portfolio Companies
With More Than $1.9 Billion
Under Management
45
Clinical Studies
Underway Within Our Portfolio
60
Diseases
Being Targeted By
Our Companies
10
of thousands
Patients Impacted
By Portfolio Company Products
and Clinical Trials